The artificial intelligence (AI)-powered Neuro Suite reportedly enables radiologists to access leading neurological AI algorithm solutions in the field, including the brain magnetic resonance imaging (MRI) segmentation capabilities of the Combinostics’ algorithm that can help differentiate degenerative pathologies such as Alzheimer’s disease and dementia.
Emphasizing timely neurological disease triage and access to “a first-in-class capability and the only open (artificial intelligence) AI architecture” for clinical AI, ConcertAI’s TeraRecon has launched Neuro Suite.
The Neuro Suite platform allows radiologists to access a variety of AI-powered neuroimaging modalities from leading vendors in the neurology field, including Combinostics, Imaging Biometrics and Cercare Medical, according to TeraRecon.
For the diagnosis of degenerative cerebral pathologies including Alzheimer’s disease and dementia, the Combinostics algorithm offers high-quality segmentation of brain magnetic resonance imaging (MRI) to help assess atrophy. TeraRecon said the algorithm from Imaging Biometrics provides radiologists with insights into the blood supply and oxygenation of brain tumors. Access to the proprietary perfusion technology of Cercare Medical enables neurovascular function assessment down to the capillary level, according to TeraRecon.
“We are proud to enhance our neurological offerings beyond TR Neuro to an entire Neuro Suite, extending to our clinician customers an amazing array of tools streamlined into one place and able to be interacted with to help identify and treat critical neurological issues,” said Dan McSweeney, the president of TeraRecon.
(Editor’s note: For related content, see “TeraRecon Launches AI-Driven Neuroimaging Platform” and “FDA Clears AI-Enabled Software for Streamlining Brain MRI Assessment and Reporting.”)
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
CT Study: AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
ACR Collaborative Model Achieves 20 Percent Improvement in PI-QUAL Scores for Prostate MRI
May 9th 2024Using a learning network model to discuss challenges and share insights among radiology departments from five different organizations, researchers noted that 87 percent of audited prostate MRI exams had PI-QUAL scores > 4 at the conclusion of the collaborative program.